Horizon Pharma plc

    [td_text_with_title custom_title=”Horizon Pharma plc”]Horizon Pharma plc is a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs.  The Company markets seven medicines through its orphan, primary care and specialty business units.  Horizon’s global headquarters are in Dublin, Ireland.[/td_text_with_title]
    Drugs

    Posts not found

    [td_text_with_title custom_title=”Latest post”]
    horizon-pharma-to-takeover-depomed

    Horizon Pharma plc Increases Offer for Depomed, Inc. to $33.00 per Share

    Price Increase Contingent on Engagement and Confirmatory Due Diligence Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced today that it has increased the value of its all-stock acquisition proposal to $33.00 per share from […]

    0 comments
    Depomed Takeover

    Horizon Pharma plc Responds to Depomed’s Adoption of a Poison Pill

    Urges Depomed to Listen to the Clear Demands of Its Shareholders DUBLIN, IRELAND — (Marketwired) — 07/13/15 — Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today responded to the announcement by Depomed, Inc. that […]

    0 comments
    [/td_text_with_title][td_text_with_title custom_title=”From Wikipedia”]

    Horizon Pharma Public Limited Company (NASDAQHZNP) is a specialty pharmaceutical company that develops and markets medicine through its subsidiaries in the United States. The company was founded in 2005 and is based in Dublin, Ireland. The company focuses on developing treatments for arthritis, pain and inflammatory diseases.[2] Horizon's product portfolio includes Actimmune (interferon gamma), Duexis (ibuprofen + famotidine), Pennsaid (diclofenac, 2% topical), and Rayos/Lodotra (prednisone).[3] In 2016, the company became a member of the Pharmaceutical Research and Manufacturers of America (PhRMA).[4]

    Business

    The company's lead product base includes DUEXIS and RAYOS. Outside the United States, RAYOS is also known as LODOTRA.[5]

    The company has cooperated with American Gastroenterological Association (AGA) Institute to launch a program named “Connect to Protect” which aims to help physicians and patients better understand non-steroidal anti-inflammatory drug (NSAID) risks. The program is planned to promote communications between physicians and patients about NSAIDs and gastrointestinal ulcers.[6]

    In March 2014, the company completed the acquisition of Vidara Therapeutics International through a merge valued at about $660 million.[7]

    In October 2014, the company acquired the U.S. sales and marketing rights to the osteoarthritis drug Pennsaid from Nuvo Research for $45 million.[8]

    In March 2015, the company acquired Hyperion Therapeutics for $1.1 billion, increasing Horizon's orphan disease drug portfolio.[9] In December, the company acquire Crealta Holdings for $510 million.[10]

    In September 2016, the company announced the acquisition of Raptor Pharmaceutical for $800 million, adding Procysbi and Quinsair to its rare drug portfolio.[11]

    In 2017, Horizon announced its intention to acquire River Vision Development Corp for $145 million, and continue the development of teprotumumab.[12]

    References

    1. ^ Horizon_Pharma_2014_Annual_Report_bmk.pdf
    2. ^ "HZNP: Summary for Horizon Pharma Inc Common Stoc- Yahoo". Finance.Yahoo.com. Retrieved 23 March 2014. 
    3. ^ "HZNP Stock News". Company Description. Retrieved 5 December 2015. 
    4. ^ "Teva wins controversial PhRMA bid despite protests from branded rivals - FiercePharma". www.FiercePharma.com. Retrieved 26 August 2017. 
    5. ^ "Marketwatch of Horizon Pharma Inc". Marketwatch.com. Retrieved 21 March 2014. 
    6. ^ "Program introduction". ConnectToProtect.com. Retrieved 21 March 2014. 
    7. ^ "Horizon Pharma to Acquire Vidara Therapeutics International". Finance.yahoo.com. 19 March 2014. Retrieved 22 March 2014. 
    8. ^ "Horizon Pharma Picks Up Nuvo's Osteoarthritis Pain Drug Pennsaid 2% - GEN News Highlights - GEN". GEN. 
    9. ^ "Horizon Pharma to Acquire Hyperion Therapeutics for $1.1B". GEN. 
    10. ^ "Horizon Pharma Buys Crealta Holdings for $510M". GEN. Retrieved 30 April 2016. 
    11. ^ "Horizon Pharma to Acquire Raptor for $800M - GEN". GEN. Retrieved 26 August 2017. 
    12. ^ "BRIEF-Horizon Pharma Plc to acquire River Vision Development Corp". 8 May 2017. Retrieved 26 August 2017 – via Reuters. 

    External links

    source: https://en.wikipedia.org/wiki/Horizon_Pharma[/td_text_with_title]